Maria JoÃ£o BonifÃ¡cio

List of Publications by Year
in descending order

18 papers	729 citations	840776 11 h-index	839539 18 g-index
19 all docs	19 docs citations	19 times ranked	659 citing authors

#	Article	IF	Citations
1	Catecholâ€Oâ€methyltransferase and Its Inhibitors in Parkinson's Disease. CNS Neuroscience & Therapeutics, 2007, 13, 352-379.	4.0	166
2	Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase. Journal of Medicinal Chemistry, 2010, 53, 3396-3411.	6.4	156
3	Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects. Clinical Pharmacokinetics, 2013, 52, 139-151.	3.5	79
4	Opicapone: a short lived and very long acting novel catecholâ€<scp>O</scp>â€methyltransferase inhibitor following multiple dose administration in healthy subjects. British Journal of Clinical Pharmacology, 2013, 76, 763-775.	2.4	76
5	Computation of the binding affinities of catecholâ€Oâ€methyltransferase inhibitors: Multisubstate relative free energy calculations. Journal of Computational Chemistry, 2012, 33, 970-986.	3.3	51
6	Pharmacological profile of opicapone, a thirdâ€generation nitrocatechol catecholâ€<scp>O</scp>â€methyl transferase inhibitor, in the rat. British Journal of Pharmacology, 2015, 172, 1739-1752.	5.4	50
7	Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Neuropharmacology, 2014, 77, 334-341.	4.1	37
8	Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor. European Journal of Pharmacology, 2003, 460, 163-170.	3.5	26
9	Discovery of a Potent, Longâ€Acting, and CNSâ€Active Inhibitor (BIA 10â€2474) of Fatty Acid Amide Hydrolase. ChemMedChem, 2018, 13, 2177-2188.	3.2	21
10	Design, synthesis, and structureâ€“activity relationships of 1,3,4-oxadiazol-2(3H)-ones as novel FAAH inhibitors. MedChemComm, 2011, 2, 889.	3.4	17
11	Effect of opicapone multipleâ€dose regimens on levodopa pharmacokinetics. British Journal of Clinical Pharmacology, 2017, 83, 540-553.	2.4	14
12	Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10â€2474. British Journal of Pharmacology, 2020, 177, 2123-2142.	5.4	11
13	A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat. Neuropharmacology, 2017, 125, 146-155.	4.1	6
14	Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration. Neuropharmacology, 2018, 143, 282-288.	4.1	4
15	Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys. European Journal of Pharmacology, 2021, 892, 173742.	3.5	4
16	Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping. Pharmacology Research and Perspectives, 2022, 10, e00891.	2.4	4
17	Absorption, metabolism and excretion of opicapone in human healthy volunteers. British Journal of Clinical Pharmacology, 2022, , .	2.4	4
18	Synthesis and structureâ€“activity relationships of ionizable 1,3,4-oxadiazol-2(3H)-ones as peripherally selective FAAH inhibitors with improved aqueous solubility. Pure and Applied Chemistry, 2016, 88, 341-347.	1.9	3